Journal of Bioequivalence & Bioavailability

International Bio Service Co., Ltd., 888 Golden Jubilee Medical Center, Mahidol University, Nakhon Pathom 73170, Thailand

Publications

• Research Article   
  Bioequivalence Study of Two Ticagrelor 90 mg Tablets in Healthy Thai Volunteers under Fasting Conditions
  Author(s): Anas Sunhem, Suchada Rakphung, Charinthon Seeduang, Sumate Kunsa-ngiem, Vipada Khaowroongrueng*, Busarat Karachot, Piengthong Narakorn, Porranee Puranajoti and Isariya Techatanawat
  
  Patients with acute coronary syndrome require antiplatelet therapy to reduce risk of thrombotic cardiovascular events. Ticagrelor is a potent oral antiplatelet agent that reversibly binds to P2Y12 Adenosine Diphosphate (ADP) receptor thereby preventing platelet aggregation. Since the use of ticagrelor is manageable in outpatient setting, the Government Pharmaceutical Organization (GPO), Thailand had developed a generic product of ticagrelor 90 mg tablets to reduce cost of treatment and improve accessibility to medicines for Thai patients. An open label, randomized, two-way crossover, single dose bioequivalence study was conducted under fasting conditions. The ANOVA showed no significant effects of sequence, formulation and period on the ln-transformed primary pharmacokinetic parameters. The 90% confidence intervals for the ratio of geometric least squares mean wer.. View more»
  

  DOI: 10.35248/0975-0851.22.S8.002

  Abstract HTML PDF